Michael Martin Breen is Executive Chairman/Interim CEO of GT Biopharma, Inc.. Currently has a direct ownership of 856,218 shares of GTBP, which is worth approximately $2.62 Million. The most recent transaction as insider was on Aug 11, 2023, when has been sold 200,000 shares (Common Stock) at a price of $0.29 per share, resulting in proceeds of $57,999. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 856K
0% 3M change
0% 12M change
Total Value Held $2.62 Million

Michael Martin Breen Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 11 2023
BUY
Grant, award, or other acquisition
$57,999 $0.29 p/Share
200,000 Added 18.94%
856,218 Common Stock
Apr 11 2023
BUY
Open market or private purchase
$25,000 $0.5 p/Share
50,000 Added 7.08%
656,218 Common Stock
Jul 15 2022
BUY
Grant, award, or other acquisition
-
278,058 Added 31.44%
606,218 Common Stock
Feb 25 2021
BUY
Conversion of derivative security
$170,347 $3.4 p/Share
50,102 Added 13.25%
328,160 Common Stock
Feb 16 2021
BUY
Grant, award, or other acquisition
-
278,058 Added 50.0%
278,058 Common Stock

Also insider at

CRKR
Creek Road Miners, Inc. Financial Services
MMB

Michael Martin Breen

Executive Chairman/Interim CEO
Brisbane, CA

Track Institutional and Insider Activities on GTBP

Follow GT Biopharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GTBP shares.

Notify only if

Insider Trading

Get notified when an Gt Biopharma, Inc. insider buys or sells GTBP shares.

Notify only if

News

Receive news related to GT Biopharma, Inc.

Track Activities on GTBP